key: cord-0800507-hyxuu9rh
authors: Bhardwaj, Prarthna V.; Emmich, Megan; Knee, Alexander; Ali, Fatima; Walia, Ritika; Roychowdhury, Prithwijit; Clark, Jackson; Sridhar, Arthi; Lagu, Tara; Loh, Kah Poh
title: Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study
date: 2021-03-24
journal: Support Care Cancer
DOI: 10.1007/s00520-021-06154-4
sha: b50047efef67c89d027b81eac65c86725a0a0c1f
doc_id: 800507
cord_uid: hyxuu9rh

PURPOSE: The Multinational Association for Supportive Care in Cancer (MASCC) score is used to risk stratify outpatients with febrile neutropenia (FN). However, it is rarely used in hospital settings. We aimed to describe management, use of MASCC score, and outcomes among hospitalized patients with FN. METHODS: We conducted a retrospective cohort study of patients with cancer and FN. We collected patient demographics, cancer characteristics, microbiological profile, MASCC score, utilization of critical care therapies, documentation of goals of care (GOC), and inpatient deaths. Outcomes associated with low- (≥ 21) versus high-risk (< 21) MASCC scores are presented as absolute differences. RESULTS: Of 193 patients, few (2%, n = 3) had MASCC scores documented, but when calculated, 52% (n = 101) had a high-risk score (< 21). GOC were discussed in 12% (n = 24) of patients. Twenty one percent (n = 40) required intermediate/ICU level of care, and 12% (n = 23) died in the hospital. Those with a low-risk score were 33% less likely to require intermediate/ICU care (95% CI 23 to 44%) and 19% less likely to die in the hospital (95% CI 10% to 27%) compared to those with high-risk score. CONCLUSIONS: MASCC score was rarely used for hospitalized patients with FN, but high-risk score was associated with worse outcomes. Education efforts to incorporate MASCC score into the workflow may help identify patients at high risk for complications and help clinicians admit these patients to a higher level of care (e.g., intermediate/ICU care) or guide them to initiate earlier GOC discussions.

Febrile neutropenia (FN) is a common complication in patients with cancer, occurring in 5-10% of patients with solid tumors [1] , 85-95% of patients with acute leukemia, and 20-25% of patients with other hematologic malignancies [2] . Neutropenia is defined as an absolute neutrophil count (ANC) of < 500 neutrophils/mcL or the combination of ANC of < 1000 neutrophils/mcL and a predicted decline of ≤ 500 neutrophils/mcL over the next 48 h. FN exists once there is a temperature ≥ 38.3°C orally or ≥ 38°C for a duration longer than 1 h with associated neutropenia [3] . FN accounts for about 40-50% of the total cost of hospitalizations in cancer care, with mortality rates ranging between 3 and 10% [4] .

Prior literature reports that 20-30% of patients with FN have an identifiable site of infection and 10-25% of patients have positive blood cultures [5] [6] [7] [8] . Experts recommend the early introduction of empiric antibiotic therapy in all patients with FN because of the high risk for progression to sepsis and death [7, 9, 10] . Historically, Pseudomonas aeruginosa was the most prevalent causative organism, but the changing microbiological profile of FN now reveals that gram-positive bacteria are more common [11, 12] .

As patients at low risk for complications could be successfully treated in the outpatient setting, several organizations including the American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), Infectious Disease Society of America (IDSA), and European Society of Medical Oncology (ESMO) recommend using the Multinational Association for Supportive Care in Cancer (MASCC) score to risk stratify patients [7, 13, 14] . Developed in 2000, the score incorporates patient and cancer characteristics to quantify the risk of FN-related complications. Higher scores indicate lower risk, with a maximum of 26 points. A cutoff value of ≥ 21 points is used to discriminate patients with low risk from those with high risk (< 21 points) for serious FN-related complications [15] . Patients identified as low risk may be managed in the outpatient setting safely with oral antibiotics. Several studies have validated this score for both hematological and solid tumors in the inpatient setting and recommend early discharge of patients with low-risk FN on oral antibiotics [16] [17] [18] [19] . Despite evidence supporting its use in the inpatient setting, MASCC score is rarely used during hospitalization [20, 21] .

FN admissions are commonly managed by hospitalists or internists rather than oncologists in the community; a tool like the MASCC score could be used to guide them around risk for clinical deterioration or death [22] . Patients with FN and lower MASCC score might be placed in a higher level of care or, alternatively, be prioritized for earlier discussion around goals of care. Therefore, we aimed to describe the management of FN among hospitalized patients with cancer, current use of MASCC score, and the association of MASCC score on presentation with poor outcomes.

Design, setting, and population We conducted a retrospective cohort study at a tertiary care academic medical center. The Institutional Review Board (IRB) at Baystate Medical Center approved this study. We identified patients hospitalized with a principal diagnosis of FN and cancer admitted to Baystate Medical Center between October 1, 2015, and April 1, 2019. Patients were included in the study if they were 18 years of age or older, were admitted to the inpatient service or intensive care unit (ICU), and carried both a diagnosis of cancer and FN. FN was identified using ICD-10 diagnosis codes (D70 and R50) in an administrative billing database. We also included patients with cancer who were admitted for an alternative diagnosis if they developed FN during their hospitalization. If patients developed multiple episodes of FN, we randomly selected a single admission for this study. We excluded patients who did not meet diagnostic criteria for FN (defined below) and those transferred out of our facility to another acute care hospital. FN related to causes other than cancer (e.g., primary immunodeficiency or liver disease) was also excluded from the study.

Data collection Two physicians (PB and ME) reviewed the electronic health record (EHR), first examining approximately 10 of the same patients' records. Any differences were resolved via discussion to standardize chart extraction and reduce inter-observer variability. Four other physicians (FA, JC, AS, and RW) who conducted chart extraction were subsequently trained by PB and ME to ensure uniformity in data collection. After collection of data, PB and ME randomly selected 75 charts for quality control purposes and confirmed uniformity of extraction methods.

Variables extracted from the EHR included patient demographics; Eastern Cooperative Oncology Group (ECOG) performance status; use of granulocyte colony-stimulating factor (GCSF) 14 days prior to or during hospitalization; documentation of MASCC score; clinical characteristics of cancer including type, stage, and cycle of chemotherapy received; microbiological profile including the presence of positive blood cultures, source of infection, initial empiric antibiotics, use of antimicrobial prophylaxis, duration of antibiotics, and documentation of goals of care discussion; and utilization of different consult services including oncology, infectious diseases, and palliative care. Clinical course including ICU level of care, septic shock requiring vasopressor use, acute respiratory failure requiring non-invasive or mechanical ventilation, documented delirium, acute kidney injury requiring hemodialysis, and inpatient death was also obtained. Admission to the ICU and the need for critical care therapies were obtained from a review of medical records. In-hospital mortality was identified by documentation of discharge status as "expired" in our billing database. All data were manually entered into the REDCap database [23] .

Definition of febrile neutropenia We defined FN based on criteria from the IDSA as an ANC of < 500 neutrophils/mcL or an ANC of < 1000 neutrophils/mcL and a predicted decline of ≤ 500 neutrophils/mcL over the next 48 h as well as a temperature of ≥ 38.3 or ≥ 38°C for longer than 1 h either prior to admission or during hospitalization when admitted for an alternative diagnosis [7] .

ECOG performance status ECOG performance status describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability [24] . It ranges from 0 to 5 with 0 indicating a fully active person who is able to carry on all pre-disease performance without restriction and 5 indicating death. This score was obtained as documented on the last oncology outpatient note prior to hospitalization or oncology consult note during hospitalization.

MASCC scoring system MASCC scores were calculated by study investigators for all patients irrespective of documentation status. We calculated the weighted MASCC risk index using the following variables: burden of illness, blood pressure, presence or absence of chronic obstructive pulmonary disease, solid tumor or hematological malignancy with or without a history of previous fungal infection, dehydration, inpatient or outpatient status at the time of onset of neutropenic fever, and age. Table 1 provides details about the calculation of the score and weighting of characteristics.

We used descriptive statistics (means, standard deviations, range, and percent as appropriate to the scale of measurement) to describe the patient sample and characteristics of those with low-versus high-risk MASCC scores. Low-versus high-risk MASCC scores were used to predict hospital outcomes such as the presence of positive blood cultures, goals of care discussions, requirement of intermediate/ICU care, and death. For each association, we estimated the area under the curve (AUC) and calculated the absolute risk difference and 95% confidence interval (CI). The analysis was conducted using Stata v16.0, StataCorp, LP, College Station, TX.

Of the 322 unique patients identified as having FN between October 1, 2015, and April 1, 2019, we excluded 129 patients; l00 patients did not meet the criteria for FN, 23 patients did not have a diagnosis of cancer, 5 patients did not meet criteria for FN or have a diagnosis of cancer, and 1 patient was transferred out of our facility. Of the 193 eligible patients, the mean age was 60 years, and more than half (107/193, 55.4%) were women. Most patients were white (162/193, 83.9%). ECOG performance status was documented for 63.7% (123/193) patients. Of these, 74.0% (91/123) had an ECOG of 0 or 1, and 7.3% (9/123) had an ECOG of 3 or 4 ( Table 2) .

Nearly half the patients (102/193, 52.5%) had hematological malignancies, with most of these being acute myeloid leukemia (33/102, 32.4%), and non-Hodgkin lymphoma ( 

Half of the patients were seen by an infectious disease specialist (98/193, 50.8%), 82.4% (159/193) were seen by a hematologist/oncologist, and 6.7% (13/193) were seen by a palliative care specialist. We observed that MASCC score was predictive of poor outcomes (AUC's ranging from 0.67 to 0.76). In particular, those with a low-risk MASCC score were 33% less likely to require intermediate/ICU care (95% CI = 23 to 44%) compared to those with a high-risk MASCC score. In addition, those with a low-risk MASCC score were 28% less likely to have a positive blood culture (95% CI = 16 to 39%) and nearly 19% less likely to die in the hospital (95% CI = 10 to 27%) compared to those with a high-risk MASCC score. Points attributed to the variable "burden of illness" are not cumulative. The maximum theoretical score is therefore 26 

In this single-center retrospective cohort of patients with FN and cancer (in which more than half of the patients had a hematologic malignancy), nearly 60% of inpatients had an identifiable source of infection with a substantial number of these testing positive for a virus. MASCC score, although rarely used, was predictive of poor outcomes. Goals of care discussions were rarely initiated, even in patients considered high risk. Our findings suggest a need for hospitalist-focused education efforts and quality improvement initiatives to incorporate MASCC score into oncologic hospitalists' workflow. The proportion of patients with an identifiable source of infection was higher than prior studies have reported [7, 25] .

Most published studies examined patients with fever and neutropenia prior to widespread use of rapid viral testing (e.g., for influenza and RSV). Notably, our study was conducted before the onset of the COVID-19 pandemic, so there were no COVID-positive patients in this sample [26] . The incidence of MRSA and Pseudomonas was low compared to other studies across the USA [7] , but most patients received empiric antibiotic therapy appropriately per current guidelines because of the high risk for progression to fatal sepsis and mortality associated with these organisms [7, 9, 10] .

Use of MASCC score among inpatients in our study was predictive of poor outcomes including the need for intermediate/ICU level care, respiratory failure necessitating ventilation, septic shock requiring vasopressor use, and [15, 19, 27, 28] . However, the Clinical Index of Stable Febrile Neutropenia (CISNE) scaore [29] , the alternative to MASCC score, has poor sensitivity and thus has limited usefulness in high-risk patients. While prior investigators have validated the MASCC score in low-risk patients hospitalized for FN, its use in high-risk patients has been less frequently studied [30] [31] [32] [33] [34] [35] . One validation study, with a goal of identifying high-risk patients who might be candidates for hematopoietic growth factor, correctly predicted 98.3% of low-risk patients and 86.4% of high-risk patients [30] . Other studies have (a) identified patients at a high risk of complications by calculating the score at 48 and 72 h, adding a measure of organ dysfunction [31] ; (b) attempted to combine MASCC score of < 21 with Creactive protein or procalcitonin to predict poor outcomes [32] [33] [34] ; and (c) examined MASCC score's calibration to identify the risk of mortality and the need for ICU level of care among patients with hematologic malignancies [35] . These studies were limited in that most were done in the ED setting, and none of them examined the use of goals of care discussions in patients with a high risk of poor outcomes.

It is not clear why goals of care were infrequently discussed with patients. We hypothesize that because neutropenic fever is a common, predictable, and manageable complication of cytotoxic therapy, there is often uncertainty regarding who should initiate these conversations. Internists may believe that goals are best discussed by the primary oncologist treating a patient's cancer. They may also fear that they lack the advanced training required to independently prognosticate various stages of cancer and navigate goals of care in those receiving active systemic therapy, especially in an era of evolving cancer therapeutics. There are also known differences in perception of cancer outcomes between physicians [36] , which may have contributed to the failure to initiate conversations. Qualitative studies would help to refine these early hypotheses.

Nearly three-quarters of patients who died during hospitalization in our cohort required intermediate/ICU level of care prior to their death. This suggests that these patients experienced clinical deterioration and, either at that time or prior to it, decided to escalate care. While this may have been consistent with patient preferences, it may also have been a missed opportunity to initiate goals of care conversation between the patient, hospitalists, and oncologists in patients with high-risk FN.

There are limitations to our study. First, it is a single-center study with a small sample size, and these results may not be generalizable to larger populations. Second, this study is a retrospective analysis with a risk of misclassification bias in calculating scores. For example, the MASCC score contains subjective characteristics like "burden of illness" and "dehydration." We did go to great lengths to standardize these definitions across reviewers. However, it is possible that those with worse outcomes were more likely to be classified with a high-risk MASCC score. Validation of the score to identify AKI acute kidney injury, ICU intensive care unit, AUC area under the curve, CI confidence interval † Per the kidney disease: improving global outcomes definition ‡ Requiring use of non-invasive ventilation like continuous positive airway pressure, bi-level continuous positive airway pressure, high-flow nasal cannula; and use of mechanical ventilation with intubation € Intermediate unit defined as a step-up or step-down unit between the general ward and ICU high-risk patients in a larger, multi-institutional sample of inpatients may be warranted. We also did not create multivariable models to examine the association between MASCC score and outcomes. Our goal, however, was primarily to demonstrate that groups with high and low MASCC scores are different, and increased utilization of this scoring system will allow hospitalists to clarify these differences and improve patient care.

In a single-center study of patients with fever and neutropenia, nearly 60% had an identifiable source of infection. Although the incidence of multidrug-resistant bacteria was low, patients mostly received empiric antibiotics appropriately to cover for these organisms to reduce the risk of sepsis and mortality per current guidelines. Patients with a high-risk MASCC score had worse outcomes, i.e., higher inpatient mortality and utilization of critical care therapies, but MASCC score was not commonly used by treating clinicians. Routine use of the MASCC score may help clinicians identify patients at high risk for complications, allowing for risk stratification at the time of admission. MASCC score could aid with triage, unit placement, and need to address and document goals of care discussions during hospitalization. Hospitalist-focused education efforts about MASCC score should be considered a way to identify patients at high risk for complications and facilitate goals of care discussions.

Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study

Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy

Myeloid growth factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

Epidemiology and source of infection in patients with febrile neutropenia: a tenyear longitudinal study

Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with Support Care Cancer cancer: 2010 Update by the Infectious Diseases Society of America

Management of fever in patients with cancer and treatment-induced neutropenia

European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the

Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation

Pseudomonas bacteremia. Retrospective analysis of 410 episodes

Invasive grampositive bacterial infection in cancer patients

Management of febrile neutropenia: ESMO Clinical Practice Guidelines

Guidelines for the use of antimicrobial agents in neutropenic patients with cancer

for the Study Section on Infections of Multinational Association for Supportive Care in Cancer (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients

Validation of MASCC score for risk stratification in patients of hematological disorders with febrile neutropenia

Prospective evaluation of Multinational Association of Supportive Care in Cancer risk index score for gynecologic oncology patients with febrile neutropenia

Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients

The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies

Utility of the Multinational Association for Supportive Care in Cancer (MASCC) risk index score as a criterion for nonadmission in febrile neutropenic patients with solid tumors

Improving the management of patients with low-risk neutropenic fever at the Cleveland Clinic Taussig Cancer Institute

Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

Research electronic data capture (REDCap)-a metadatadriven methodology and workflow process for providing translational research informatics support

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Bacteraemia in febrile neutropenic cancer patients

Rapoport B Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer

Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice

Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications

Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients

Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score

Patients neutropéniques fébriles à bas et haut risques

Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia

Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia

Independent factors for prediction of poor outcomes in patients with febrile neutropenia

C-reactive protein and the MASCC risk index identify high-risk patients with Support Care Cancer febrile neutropenia and hematologic neoplasms

Physician perceptions about goals of care of hospitalized patients with malignancies

Clinical research in febrile neutropenia in cancer patients: past achievements and perspectives for the future

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Acknowledgment The project utilized a REDCap database funded by